(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 156.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Abeona Therapeutics's revenue in 2026 is $14,540,000.On average, 9 Wall Street analysts forecast ABEO's revenue for 2026 to be $3,715,627,428, with the lowest ABEO revenue forecast at $2,364,044,583, and the highest ABEO revenue forecast at $5,210,724,045. On average, 9 Wall Street analysts forecast ABEO's revenue for 2027 to be $8,870,724,212, with the lowest ABEO revenue forecast at $7,003,563,295, and the highest ABEO revenue forecast at $11,254,261,134.
In 2028, ABEO is forecast to generate $13,901,115,622 in revenue, with the lowest revenue forecast at $10,807,419,205 and the highest revenue forecast at $17,115,641,743.